The signalling pathways activated in PaSCs in response to contact with cancer cells will be an interesting platform on which to develop therapies targeting PaSCs, i.e., MAP kinase, PDGF, FGF, transforming growth factor β (TGFβ), connective tissue growth factor (CTGF) and epidermal growth factor (EGF) [179]. This evidence concerns the gene TGFB1 and cancer.